Ebola Vaccine Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Viruses, Vol. 15, Pages 776: Host Cell Targets for Unconventional Antivirals against RNA Viruses
ómez The recent COVID-19 crisis has highlighted the importance of RNA-based viruses. The most prominent members of this group are SARS-CoV-2 (coronavirus), HIV (human immunodeficiency virus), EBOV (Ebola virus), DENV (dengue virus), HCV (hepatitis C virus), ZIKV (Zika virus), CHIKV (chikungunya virus), and influenza A virus. With the exception of retroviruses which produce reverse transcriptase, the majority of RNA viruses encode RNA-dependent RNA polymerases which do not include molecular proofreading tools, underlying the high mutation capacity of these viruses as they multiply in the host cells. Together with their...
Source: Viruses - March 17, 2023 Category: Virology Authors: Vicky C. Roa-Linares Manuela Escudero-Fl órez Miguel Vicente-Manzanares Juan C. Gallego-G ómez Tags: Review Source Type: research

Viruses, Vol. 15, Pages 698: Viral Vectors in Gene Therapy: Where Do We Stand in 2023?
m Viral vectors have been used for a broad spectrum of gene therapy for both acute and chronic diseases. In the context of cancer gene therapy, viral vectors expressing anti-tumor, toxic, suicide and immunostimulatory genes, such as cytokines and chemokines, have been applied. Oncolytic viruses, which specifically replicate in and kill tumor cells, have provided tumor eradication, and even cure of cancers in animal models. In a broader meaning, vaccine development against infectious diseases and various cancers has been considered as a type of gene therapy. Especially in the case of COVID-19 vaccines, adenovirus-based ...
Source: Viruses - March 7, 2023 Category: Virology Authors: Kenneth Lundstrom Tags: Review Source Type: research

Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSV ΔG-ZEBOV-GP)
Vaccine. 2023 Jan 30:S0264-410X(23)00090-7. doi: 10.1016/j.vaccine.2023.01.059. Online ahead of print.ABSTRACTWhile effective at preventing Zaire ebolavirus (ZEBOV) disease, cellular immunity to ZEBOV and vector-directed immunity elicited by the recombinant vesicular stomatitis virus expressing ZEBOV glycoprotein (rVSVΔG-ZEBOV-GP) vaccine remain poorly understood. Sera and peripheral blood mononuclear cells were collected from 32 participants enrolled in a prospective multicenter study [ClinicalTrials.gov NCT02788227] before vaccination and up to six months post-vaccination. IgM and IgG antibodies, IgG-producing memory B ...
Source: Vaccine - February 1, 2023 Category: Allergy & Immunology Authors: Vanessa Raabe Lilin Lai Juliet Morales Yongxian Xu Nadine Rouphael Richard T Davey Mark J Mulligan Source Type: research

Hendra Virus
Hendra virus (HeV) emerged as a zoonotic pathogen in the 1990s, causing low morbidity but high mortality in humans and horses. Pteropid bats are the natural reservoir of HeV and other important zoonotic viruses such as Nipah and Ebola viruses. Equivac HeV, manufactured by Zoetis (Parkville, Victoria, Australia), is the only commercially available vaccine for horses. There is no commercial vaccine for humans. The epidemiology, clinical features, pathology, diagnosis, management, and prevention of HeV will be reviewed. (Source: Veterinary Clinics of North America: Equine Practice)
Source: Veterinary Clinics of North America: Equine Practice - February 1, 2023 Category: Veterinary Research Authors: Xueli Wang, Jessica C. Wise, Allison J. Stewart Source Type: research

Application of Cell Penetrating Peptides as a Promising Drug Carrier to Combat Viral Infections
Mol Biotechnol. 2023 Jan 31. doi: 10.1007/s12033-023-00679-1. Online ahead of print.ABSTRACTNovel effective drugs or therapeutic vaccines have been already developed to eradicate viral infections. Some non-viral carriers have been used for effective drug delivery to a target cell or tissue. Among them, cell penetrating peptides (CPPs) attracted a special interest to enhance drug delivery into the cells with low toxicity. They were also applied to transfer peptide/protein-based and nucleic acids-based therapeutic vaccines against viral infections. CPPs-conjugated drugs or vaccines were investigated in several viral infectio...
Source: Herpes - January 31, 2023 Category: Infectious Diseases Authors: Niloofar Khairkhah Ali Namvar Azam Bolhassani Source Type: research

U.S. scientists brace for tighter scrutiny of potentially risky research
Federally funded scientists who work with potentially harmful bacteria, viruses, and other agents could soon face a major expansion of U.S. government oversight. An expert group last week recommended broadening rules that require universities and funding agencies to determine whether proposed studies count as dual-use research—work that carries the risk of intentionally or accidentally creating a bioweapon. Currently, such reviews are only required for experiments involving 15 dangerous agents. But the panel argues the reviews should now extend to work with all human, plant, and animal pathogens, even those causing only ...
Source: Science of Aging Knowledge Environment - January 30, 2023 Category: Geriatrics Source Type: research

Structure of the Inmazeb cocktail and resistance to Ebola virus escape
Cell Host Microbe. 2023 Jan 20:S1931-3128(23)00022-7. doi: 10.1016/j.chom.2023.01.002. Online ahead of print.ABSTRACTMonoclonal antibodies can provide important pre- or post-exposure protection against infectious disease for those not yet vaccinated or in individuals that fail to mount a protective immune response after vaccination. Inmazeb (REGN-EB3), a three-antibody cocktail against Ebola virus, lessened disease and improved survival in a controlled trial. Here, we present the cryo-EM structure at 3.1 Å of the Ebola virus glycoprotein, determined without symmetry averaging, in a simultaneous complex with the antibodies...
Source: Cell Host and Microbe - January 28, 2023 Category: Microbiology Authors: Vamseedhar Rayaprolu Benjamin O Fulton Ashique Rafique Emilia Arturo Dewight Williams Chitra Hariharan Heather Callaway Amar Parvate Sharon L Schendel Diptiben Parekh Sean Hui Kelly Shaffer Kristen E Pascal Elzbieta Wloga Stephanie Giordano Nicole Negron Source Type: research

Recent updates on correlates of vaccine-induced protection
Correlates of protection are key for vaccine development against any pathogen. In this paper we summarize recent information about correlates for vaccines against dengue, Ebola, influenza, pneumococcal, respiratory syncytial virus, rotavirus, shigella, tuberculosis and Zika virus. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - January 27, 2023 Category: Allergy & Immunology Source Type: research

Protein decoys for viruses may battle COVID-19 and more
As the fight against COVID-19 wears on and the virus continues to mutate, vaccines and several monoclonal antibody drugs are losing some of their punch. That’s added urgency to a strategy for preventing and treating the disease that, in theory, could stop all variants of SARS-CoV-2. The idea is to flood the body with proteins that mimic the angiotensin-converting enzyme 2 (ACE2) receptor, the cell-surface protein that SARS-CoV-2 uses to gain entry into cells. These decoys would bind to the virus’ spike protein, disarming it. The molecules might both protect people from getting infected and help COVID-19 patients clear ...
Source: Science of Aging Knowledge Environment - January 26, 2023 Category: Geriatrics Source Type: research